Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.

Journal of neurochemistry - 1 Oct 2016

Rodrigues Filipe Brogueira, Byrne Lauren, McColgan Peter, Robertson Nicola, Tabrizi Sarah J, Leavitt Blair R, Zetterberg Henrik, Wild Edward J

Abstract excerpt

Huntington's disease (HD) is a hereditary neurodegenerative condition with no therapeutic intervention known to alter disease progression, but several trials are ongoing and biomarkers of disease progression are needed. Tau is an axonal protein, often altered in neurodegeneration, and recent studies pointed out its role on HD neuropathology. Our goal was to study whether cerebrospinal fluid (CSF) tau is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Enzyme-Linked Immunosorbent Assay

Share to Huntington Disease

Share to Pilot Projects

Share to Predictive Value of Tests

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27344050
DOI: 10.1111/jnc.13719
PMCID: PMC5053298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.PMID 27344050Read ↗

Cerebrospinal Fluid Biomarkers for Huntington’s DiseaseSemantic proximity Read ↗

The role of tau in the pathological process and clinical expression of Huntington's disease.Semantic proximity Read ↗

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patientsSemantic proximity Read ↗

Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapiesSemantic proximity Read ↗

Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severitySemantic proximity Read ↗

Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington’s diseaseSemantic proximity Read ↗

Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.Semantic proximity Read ↗

Analysis of mutant and total huntingtin expression in Huntington's disease murine models.Semantic proximity Read ↗

Salivary levels of total huntingtin are elevated in Huntington’s disease patientsSemantic proximity Read ↗

High Levels of Mutant Huntingtin Protein in Tear Fluid From Huntington’s Disease Gene Expansion CarriersSemantic proximity Read ↗

Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosisSemantic proximity Read ↗

Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.